This project aims to 1) investigate transdiagnostic processes in patients with anxiety disorders, PTSD, OCD and depressive disorders with and without comorbidity, 2) relate these processes to severity of symptoms, treatment progress, and relapse.…
ID
Source
Brief title
Condition
- Psychiatric disorders NEC
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The main study parameters at all timepoints across all groups are: the severity
of anxiety and depressive symptoms (assessed with the BAI and IDS-SR), RNT and
avoidance (assessed with the RRS, PSWQ, MRNT; BFT, CBAS, BEAQ and Manikin
task), cognitive control (assessed with the ATQ-short and IST).
Secondary outcome
The secondary study outcome differ per group, see below.
Across all patient groups: Intolerance of uncertainty, perceived criticism and
general clinical outcomes (assessed with the IUS, PC and OQ, respectively).
Anxiety group only: Autobiographical specificity and selectivity (assessed with
the AMT and AMT-F in anxiety disorders and stress-related disorders),
autobiographical memory function (assessed with the TALE), problem-solving
ability (assessed with the MEPS), disorder specific symptom measures for SAD
(assessed with the LSAS), panic disorder (assessed with the PDSS-SR) and
agoraphobia (assessed with the Mobility Inventory).
Depression group only: Anhedonia (assessed with the DARS-NL and SHAPS-NL),
autobiographical specificity and selectivity (assessed with the SRET in
depressive disorders), physical activity (as clinical outcome; assessed with
the IPAQ).
PTSD and OCD groups only: Autobiographical specificity and selectivity
(assessed with the AMT and AMT-F), autobiographical memory function (assessed
with the TALE), problem-solving ability (assessed with the MEPS), disorder
specific symptom measures for PTSD and OCD (assessed with the PSS-SR and Y-BOCS
respectively).
Background summary
Anxiety, post-traumatic stress disorder (PTSD) and obsessive-compulsive
disorder are all found to be highly comorbid with depression(37-48%). This
comorbidity has been linked to more severe symptoms accompanying each
diagnosis, poorer treatment outcomes, and early treatment drop-out. Despite the
impact of comorbidity, most research focuses on processes in mental disorders
without comorbidity. In order to gain more knowledge about comorbidity in the
development of symptoms and treatment outcomes, it is important to investigate
the role of transdiagnostic processes within anxiety, OCD, PTSD and/or comorbid
depressive complaints. Transdiagnostic processes are processes implicated in a
wide range of psychopathological disorders, and hence are observed across
disorders. Relevant transdiagnostic cognitive processes related to anxiety,
OCD, PTSD and depression are repetitive negative thinking (RNT), avoidance,
cognitive control, and autobiographical memory bias. These transdiagnostic
processes contribute to the development, maintenance and exacerbation of
anxiety and depression.
Study objective
This project aims to 1) investigate transdiagnostic processes in patients with
anxiety disorders, PTSD, OCD and depressive disorders with and without
comorbidity, 2) relate these processes to severity of symptoms, treatment
progress, and relapse. This can help understand why treatment works or does not
work for patients that have these disorders in the presence of absence of
comorbidity. In addition, it aids in the development of new interventions and
personalised treatments in specialized mental healthc
Study design
This is a naturalistic, observational study with a longitudinal design. This
design
is suitable to observe changes in cognitive processes over the course of
treatment and to
predict treatment outcome and relapse using data of intermediate changes
assessed during different time points.
Assessments will be done before start of treatment (Timepoint 1, baseline,
experimental assessment), and then every three months. That is, after 3 months
(Timepoint 2, online assessment), 6 months (Timepoint 3, experimental
assessment), 9 months (Timepoint 4, online assessment), 12 months (Timepoints
5, online assessment), and 24 months (Timepoint 6, follow-up, online
assessment).
The second experimental assessment (Timepoint 3) is planned after 6 months as
most of the treatment programs take between 15-25 sessions. Relevant treatment
progress directly after treatment, may thus be best observed after 6 months.
Study burden and risks
There is no risk involved in the assessments using questionnaires, experimental
tasks and the heart-rate registration via the sport watch.. Nevertheless,
performance on (repeated) experimental tasks and completing questionnaires
during assessment might impose some burden on participants. According to the
NFU brochure *Kwaliteitsborging mensgebonden onderzoek 2.0*, the overall risk
classification of this study is *negligible risk*.
Tarweweg 2
Nijmegen 6534 AM
NL
Tarweweg 2
Nijmegen 6534 AM
NL
Listed location countries
Age
Inclusion criteria
Current (primary) Axis I diagnosis of anxiety (GAD, Social Phobia, Panic
Disorder, Agoraphobia), PTSD or OCD and/or depression (MDD, Persistent
Depressive Disorder) diagnosis (assessed using the Mini-international
Neuropsychiatric Interview)
From age 18 onwards
Fluent in Dutch
Able to give Informed Consent
Exclusion criteria
Insufficient comprehension of the Dutch language
Physical, cognitive, or intellectual impairments interfering with
participation, such as deafness, blindness, or sensorimotor handicaps
Diagnosis of bipolar disorder, schizophrenia, schizophreniform disorder,
schizoaffective illness
Current psychosis
Drug or alcohol addiction in the past 6 months
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL72055.091.20 |